Shares of Oxford Immunotec Global OXFD remained unaffected at $11.76 after the company reported Q1 results.
Quarterly Results
Earnings per share were down 233.33% over the past year to ($0.20), which missed the estimate of ($0.15).
Revenue of $13,911,000 less by 5.94% from the same period last year, which beat the estimate of $13,450,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Q2 revenue expected between $5,000,000 and $6,000,000.
How To Listen To The Conference Call
Date: May 05, 2020
Time: 10:01 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/g5rzprwm
Price Action
52-week high: $17.77
52-week low: $8.37
Price action over last quarter: down 10.98%
Company Overview
Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.